Franklin Biotechnology Discovery R6 FRBRX
Set alert
197.48 USD -2.50 -1.25%
At close
Day range unavailable
173.67 52-week range 231.92
- YTD
- +10.04%
- 1 year
- +9.08%
- Open
- —
- Prev close
- 199.98
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 152.71
- 200-d avg
- 150.97
2Y chart
Events in this range
- Dec 22, 2025Dividend: 18.4014
Signals (91)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 20, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 12, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 4 weeks ago |
| RSI: Oversold | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jun 26, 2026 | 4 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
Newest 20 of 91.
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 152.71
- 200-day average
- 150.97
About Franklin Biotechnology Discovery R6
Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on FRBRX — it syncs with the Stock Master app.